Insider Selling: Evolus, Inc. (NASDAQ:EOLS) CFO Sells $49,074.48 in Stock

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the sale, the chief financial officer now owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Evolus Stock Performance

NASDAQ:EOLS opened at $15.27 on Thursday. The business has a 50 day moving average of $13.44 and a 200 day moving average of $13.00. The company has a market capitalization of $963.38 million, a price-to-earnings ratio of -14.54 and a beta of 1.30. Evolus, Inc. has a 1-year low of $7.44 and a 1-year high of $16.29. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67.

Evolus (NASDAQ:EOLS) last released its earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The company had revenue of $66.91 million during the quarter, compared to the consensus estimate of $65.06 million. On average, sell-side analysts predict that Evolus, Inc. will post -0.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on EOLS. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a research report on Monday. Finally, HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, August 1st.

Hedge Funds Weigh In On Evolus

A number of large investors have recently bought and sold shares of the stock. Perceptive Advisors LLC increased its stake in Evolus by 166.8% in the 4th quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock worth $41,735,000 after purchasing an additional 2,477,623 shares during the period. Assenagon Asset Management S.A. increased its stake in Evolus by 5,627.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock worth $10,276,000 after purchasing an additional 930,566 shares during the period. Lord Abbett & CO. LLC purchased a new position in Evolus in the 1st quarter worth approximately $11,628,000. BNP Paribas Financial Markets increased its stake in Evolus by 84.2% in the 1st quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock worth $5,683,000 after purchasing an additional 185,532 shares during the period. Finally, Armistice Capital LLC purchased a new position in Evolus in the 2nd quarter worth approximately $3,906,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.